Stockreport

Travere Therapeutics: Still Undervalued Post FSGS Approval [Seeking Alpha]

Travere Therapeutics, Inc.  (TVTX) 
PDF TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari's commercial lau [Read more]